首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
目的:探讨贲门失弛缓症患在气囊扩张加食管下括约肌(LES)内注射肉毒杆菌毒素(BT)组(联合组)和气囊扩张组(扩张组)治疗前后食管动力学特征以及与疗效的关系。方法:贲门失也缓症患30例,所有患根据临床症状、钡餐、内镜和食管测压确诊,确诊后联合治疗14例,单纯气囊扩张治疗16例。监测治疗后、治疗后3d、3个月及1年的临床积分及测压指标。结果:两组患经治疗后临床症状明显改善,且持续1年。治疗后3d、3个月和1年,两组LES压力(LESP)和LES松弛率(LESR)与治疗前相比,均有明显改善(P<0.05),联合组LESP下降明显,较扩张组相差显(P<0.05)。治疗前全部患食管体部均为非推进性同步收缩波,治疗后联合组1例恢复为推进性收缩波,较扩张组相差显(P<0.05)。治疗前全部患食管体部均为非推进性同步收 缩波,治疗后联合组1例恢复为推进性收缩波,而单纯气囊扩张组无改善。结论:气囊扩张加LES内注射BT联合治疗贲门失弛缓症疗效较好,不仅降低LESP,而且改善LESR,缓解临床症状,疗效较单纯气囊扩张治疗为佳。食管测压是主要的随访方法,LESP和LESR是有效的动力学监测指标。  相似文献   

2.
目的:探讨贲门失弛缓症患者食管动力学改变及气囊扩张联合肉毒毒素(BT)注射治疗的疗效。方法:在内镜及X线监视下,用3cm OTW气囊对56例患者先扩张后注射肉毒毒素,扩张压力为80~155kPa,维持30s~1min,反复2~3次。然后注射BT100u。结果:56例患者临床症状显著改善,可进半流食和普食。13例患者治疗前LES压力(7.86±1.42)kPa,扩张治疗后LES压力较治疗前明显下降(P<0.01)。结论:小气囊扩张术联合肉毒毒素注射治疗贲门失弛缓症具有疗效高、持续时间长、患者痛苦小等特点,值得临床推广使用。  相似文献   

3.
安毅 《陕西医学杂志》2010,39(7):855-856
目的:探讨贲门失弛缓症治疗的有效方法。方法:选择贲门失弛缓症患者89例,A组28例内镜下气囊扩张术治疗,B组32例应用肉毒杆菌毒素局部注射治疗,C组29例肉毒杆菌毒素联合小气囊扩张治疗。结果:治疗后A组有效率96.43%,B组有效率96.88%,C组有效率100%,三组比较无显著性差异;治疗后2年A组有效率85.71%,B组有效率71.88%,C组有效率93.10%,C组优越于A、B两组。结论:经内镜注射肉毒杆菌毒素联合小气囊扩张治疗贲门失弛缓症近期疗效尚好,远期疗效有待进一步观察。  相似文献   

4.
阮海兰 《西部医学》2009,21(8):1370-1372
目的探讨气囊扩张联合肉毒毒素局部注射治疗贲门失弛缓症的临床效果。方法贲门失弛缓症患者28例随机等分为扩张组和联合组,前者仅用气囊扩张治疗,后者接受气囊扩张治疗后,在内镜直视下食管括约肌(LES)内注射A型肉毒毒素治疗。术前、治疗后3、12和24个月随访观察两组患者的临床效果、下食管括约肌的压力(LESP)、松弛率(LESRR)及贲门口内径、5min存留钡柱高度等。结果在治疗后3个月时联合组与扩张组的临床效果相比差异无统计学意义(P〉0.05),但12和24个月时,联合组的临床效果高于扩张组;治疗前后LESP和LESRR的差值,联合组均高于扩张组;治疗后3个月贲门口直径、5min存留钡高度两组无统计学差异(P〉O.05),治疗后12和24个月两组的贲门口直径、5min存留钡高度有统计学差异(P〈O.05)。结论气囊扩张联合肉毒毒素局部注射治疗贲门失弛缓症,具有疗效高、持续时间长、患者痛苦小等优点,是治疗责门失弛缓症的有效方法之一。  相似文献   

5.
贲门失弛缓症的治疗   总被引:6,自引:0,他引:6  
焦红梅  谢鹏雁 《中国医刊》2003,38(10):17-18
贲门失弛缓症的治疗目的是降低LES压力 ,缓解吞咽困难和预防不可逆的食管损伤。目前该病的治疗方法有药物治疗、肉毒毒素注射、气囊扩张和外科手术。2 0 0 1年美国学者Richter比较了贲门失弛缓症的几种治疗方法的疗效和费用 ,推荐治疗贲门失弛缓症的经济实用方案 :适宜行手术的有症状患者可根据医师的建议和经验 ,选择分级气囊扩张或腹腔镜Heller术 ;气囊扩张治疗无效者应行肌切开术 ;对于不宜行手术者 ,开始可注射肉毒毒素 ,无效者用硝苯地平和硝酸异山梨酯可能有效 ;巨食管 (乙状食管 ,直径大于 8cm)或LES压力低而有持续症状的患者可…  相似文献   

6.
陈保银  马竹芳 《吉林医学》2011,(35):7493-7494
目的:探讨肉毒杆菌毒素注射治疗贲门失弛缓症的临床疗效。方法:对24例贲门失弛缓症行内镜下食管下括约肌内注射肉毒杆菌毒素。结果:治疗后症状得到不同程度地改善。结论:食管下括约肌内注射肉毒杆菌毒素治疗贲门失弛缓症疗效好,安全易行。  相似文献   

7.
贲门失弛缓症58例临床分析   总被引:1,自引:0,他引:1  
目的:探讨贲门失迟缓症患者食管动力学改变,观察气囊扩张与肉毒碱注射治疗贲门失弛缓症对食管动力学的影响。方法:将经X线钡剂造影、内镜检查、食管动力学检查确诊的58例贲门失迟缓症患者随机分组。分别采用瑞典CTD PC Polyraf多导消化管动力检测仪对58例患者分别于扩张治疗前后作了下食管括约肌(LES)压力及其松弛压(LESP)与松弛率(LESRR)、食管体腔内压力、干咽蠕动以及食管内24hpH检测,并在内镜或X线监视下,用气囊扩张,压力为138kPa,持续10~30s,重复2~3次。并联合肉毒素(BT)于下食管括约肌内注射治疗。结果:治疗前LES压力为7.59±1.43kPa,松弛率为35.6%,食管体部腔内压力为6.08±2.73kPa,干咽时食管无蠕动,扩张治疗后LES压力为3.12±1.57kPa,均明显降低,松弛率明显升高(P<0.01)。扩张治疗前后食管24hpH检测显示无异常反流,临床表现明显改善,可进半流质及普食。58例均未发生任何并发症。结论:贲门失迟缓症患者存在明显动力障碍,BT注射治疗与气囊扩张联合治疗效果比单一BT注射更明显,都不会造成胃食管反流。  相似文献   

8.
目的 评估贲门失弛缓症患者的食管动力学和临床症状,对比内镜下水囊扩张及肉毒毒素注射两种方法的疗效.方法 采用前瞻性随机对照研究方法,选取临床初次确诊为原发性贲门失弛缓症的患者共80例,随机分为2组,分别接受内镜下水囊扩张和肉毒毒素注射治疗.记录患者治疗前及治疗后1周、1个月的临床症状评分和食管动力学指标,并记录随访12个月内患者的缓解率情况.结果 两组患者治疗后1周、1个月的临床症状积分(总体症状、反食、吞咽困难、胸痛)和食管动力学指标(下食管括约肌静息压和松弛率、食管体部收缩幅度及顺行性收缩百分比)较治疗前均有改善(P<0.01).治疗后1周水囊扩张组反食、吞咽困难症状积分的改善优于肉毒毒素注射组(P<0.05,P<0.01),治疗后1周和1个月水囊扩张组下食管括约肌静息压的改善优于肉毒毒素注射组(P<0.01).术后12个月水囊扩张组和肉毒毒素注射组临床缓解率分别为73.2%和61.5%,Kaplan-Meier法分析显示术后12个月两组累积缓解率差异无统计学意义(P=0.29).结论 内镜下水囊扩张和肉毒毒素注射两种方法治疗贲门失弛缓症均有效,而且前者的治疗效果更好.  相似文献   

9.
目的 评价气囊扩张治疗贲门失弛缓症的疗效,并探讨术前患者下食管括约肌静息压可否作为气囊扩张治疗压力选择的依据.方法 45例贲门失弛缓症患者,17例为对照组,28例为研究组.研究组中再根据术前下食管括约肌压力分为两组,压力大于20mmHg为一组(20例),小于、等于20mmHg为一组(8例).所有病例均在胃镜直视下行气囊扩张术,测定治疗前、治疗后3d的下食管括约肌静息压、下食管括约肌松弛率,进行对比分析;并且随访半年,观察症状积分.结果 研究组和对照组全部45例患者经扩张治疗后临床症状明显缓解,症状评分由(5.1±0.6)降至(1.3±0.6) (P<0.05).其中研究组中的2组患者从症状评分和术后3d LESP、LESR的组间比较分析,气囊扩张治疗有效,且近期疗效无明显差异.结论 气囊扩张治疗贲门失弛缓症的近期疗效肯定,术前下食管括约肌压力的高低可作为扩张治疗时气囊压力的选择指标.  相似文献   

10.
张建成  周雨迁 《中外医疗》2011,30(36):87-88
目的 探讨内镜下单纯气囊扩张与联合肉毒毒素注射序贯治疗贲门失弛缓症的临床疗效.方法 回顾性分析2006年2月至2009年7月在湘雅二医院行单纯气囊扩张和联合肉毒毒素注射序贯治疗贲门失弛缓症患者各38例,于治疗后3个月、1、2年随访观察2组患者的临床疗效、贲门口内径、5min存留钡柱高度.结果 联合序贯组治疗后3个月、1...  相似文献   

11.
FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…  相似文献   

12.
Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.  相似文献   

13.
In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.  相似文献   

14.
Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.  相似文献   

15.
16.
目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P<0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P<0.05),PaCO2均随观察时间的延长而降低(P<0.05).观察组治疗有效率为87.5%,显著高于对照组的70.0% (P <0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P<0.05),且观察组明显低于对照组(P<0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.  相似文献   

17.
Evidence obtained from randomized controlled trials (RCTs) has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine (TCM) and results have shown that there is an urgent need for higher quality RCTs on TCM.  相似文献   

18.
Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.  相似文献   

19.
20.
CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号